BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease ...
Nasdaq4d
BioRestorative Therapies, Inc. Receives FDA IND Clearance for BRTX-100 to Treat Chronic Cervical Discogenic Pain
The company is planning a Phase 2 study for BRTX-100, indicating progress in clinical development and commitment to addressing chronic cervical discogenic pain, which affects a large segment of ...
Morningstar5d
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
MELVILLE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical ...
Stockhouse4d
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
MELVILLE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the ...
manilatimes5d
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
The pain can range from cervical intervertebral discs, facet joints to atlantoaxial joints. Cervical discogenic pain syndrome is a common source of neck pain with a reported prevalence between 16% to ...
BioRestorative Therapies, Inc: BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting - - IND clearance expands Company's advanced clinical pipeline for ...